2021 annual financial data

Inhibikase Therapeutics, Inc. 2021 Net margin

Inhibikase Therapeutics, Inc. 2021 net margin with verified reported values.

Direct answer

Net margin was -477.52%.

Operating income was -14,766,140 USD and net income was -14,805,986 USD.
Operating cash flow was -14,297,051 USD.

Get free Inhibikase Therapeutics, Inc. email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
3,100,605 USD
Operating income
-14,766,140 USD
Net income
-14,805,986 USD
Operating cash flow
-14,297,051 USD